ACOG

A scoping review presented at ACOG 2026 by Calbeth C. Alaribe, DMSc, MPH, PA-C, found no studies examining the association between preeclampsia, eclampsia, and endometriosis among Black women.

Experts explain the role and safety of Bayer's elinzanetant to treat vasomotor symptoms since its approval in October 2025.

Nishita Pondugula, MD, MS, explains her session surrounding associations of gestational weight gain and hypertensive pregnancy disorders with prepregnancy GLP-1 exposure.

The vacuum device was favored on three measures: lower ICU admission (5% vs 12%), lower blood transfusion rates (48% vs 62%), and shorter indwelling time (by 1.96 hours), all P <.001.

Research presented at ACOG suggests that gaps exist in sexual medicine education across Midwestern medical schools, potentially leading to underprepared graduates.

Eduardo Lara-Torre, MD, FACOG, emphasizes that pediatric and adolescent gynecology provides a critical bridge to ensure young patients do not lose access to care as they transition to adult providers.

A novel methylation signature may help identify patients unlikely to respond to progestin therapy, according to Hugh Taylor, MD.

Genevieve Neal-Perry, MD, PhD, highlights that phase 4 real-world data confirm that fezolinetant significantly reduces VMS bother, particularly in high-burden groups such as Black women and patients with obesity.

Progressive menstrual pain should prompt earlier evaluation for endometriosis to prevent missed opportunities and delayed care, Hugh Taylor, MD, explained.

David Shalowitz explains why experts now recommend a dual approach for most patients with postmenopausal bleeding due to limitations in ultrasound accuracy.

Earlier initiation of conservative therapies may improve outcomes and reduce the need for advanced treatment in stress urinary incontinence.

At ACOG, David Shalowitz, MD, highlighted the biggest takeaways from April's updated guidance on postmenopausal bleeding.

Early postpartum visits were associated with a 44% reduction in acute care use among patients with SUD, regardless of care model.

Eduardo Lara-Torre, MD, FACOG, explains that the unbundling of obstetric codes on January 1, 2027, will allow physicians to bill for each visit individually rather than receiving a single bundled payment.

Members of the BillionToOne team joined us at ACOG to discuss the launch of the new Unity Confirm fetal cell-based test for confirmation of high-risk prenatal screening results.

At ACOG 2026, we spoke with Akiva Novetsky, MD, MS, and Kimberly Gecsi, MD, about recent updates to cervical cancer screening guidelines.

According to Erick Holder, MD, AI tools can help combat medical misinformation by directing patients toward scientific research and board-certified specialists.

While neonatal outcomes remained stable, the use of piperacillin-tazobactam for chorioamnionitis was linked to a significantly longer maternal readmission length of stay.

Take a look back at our coverage (so far) of the 2026 ACOG meeting in Washington, DC

At ACOG, Julie Anderson presented data demonstrating that virtual birth planning is associated with a nearly 4-fold increase in shared decision-making for high-risk patients.

Meaningful improvements in gynecologic care for LGBTQ patients require both environmental changes—inclusive waiting rooms, trained front desk staff, flexible scheduling—and clinical recalibration, including routine screening for contraceptive needs and menopausal symptoms regardless of gender identity or presentation.

Pelin Batur, MD, emphasizes that half of patients are unsatisfied with their sexual health and clinicians should normalize these concerns through simple, open-ended questions.

Jill Liss, MD, MSCP, FACOG, outlines aspects of hormonal and non-hormonal treatments for vasomotor symptoms.

During clinical validation done by the company, Unity Confirm demonstrated 100% concordance with known fetal outcomes and invasive diagnostic results in 16 samples.

In this discussion from ACOG's 75th Annual Meeting, Genevieve Neal-Perry, MD, PhD, explains how elinzanetant has impacted patients since it's approval in October 2025.

Molly Dickinson, DO, describes a rare case where a 22-week uterine rupture was repaired allowing the pregnancy to continue to a successful 32-week delivery.

A study of 1206 women found that while many remain sexually active as they age, a higher number of menopausal symptoms was linked to decreased sexual satisfaction.

Contemporary OB/GYN will be on site in Washington, D.C. to cover the latest data out of the 75th Annual ACOG Clinical & Scientific Meeting.

From FDA regulatory updates for products related to women's health, to a preview of upcoming annual meetings and conferences, we keep you updated on what's to come in Q2 of 2026.

A recent study presented at ACOG 2025 highlights the potential of once-weekly secnidazole oral granules as an effective long-term therapy for recurrent bacterial vaginosis.